anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Resistance of cancers to treatments, such as chemotherapy, largely arise due to cell mutations. These mutations allow cells to resist apoptosis and inevitably lead to recurrence and often progression to more aggressive cancer forms. Sustained-low dose therapies are being considered as an alternative over maximum tolerated dose treatments, whereby a smaller drug dosage is given over a longer period of time. However, understanding the impact that the presence of treatment-resistant clones may have on these new treatment modalities is crucial to validating them as a therapeutic avenue. In this study, a Moran process is used to capture stochastic mutations arising in cancer cells, inferring treatment resistance. The model is used to predict the probability of cancer recurrence given varying treatment modalities. The simulations predict that sustained-low dose therapies would be virtually ineffective for a cancer with a non-negligible probability of developing a sub-clone with resistance tendencies. Furthermore, calibrating the model to in vivo measurements for breast cancer treatment with Herceptin, the model suggests that standard treatment regimens are ineffective in this mouse model. Using a simple Moran model, it is possible to explore the likelihood of treatment success given a non-negligible probability of treatment resistant mutations and suggest more robust therapeutic schedules.
Human antigen-presenting cells (APC), on which the costimulatory ligands CD40, CD80 and CD86 are blocked e.g. by antibodies, are unable to fully activate allogeneic T cells in vitro. Instead, they induce a long-lasting functional T cell alteration with lack of IL-2, IL-5 and IL-13 production upon allogeneic restimulation. Present invention demonstrates that despite costimulation blockade during in vitro allogeneic stimulation, a non-proliferating responder T cell subpopulation is activated to express ICOS. Removal of these ICOS-expressing cells restores the capacity of reciprocal ICOS negative cells to proliferate and to produce Th1 and Th2 cytokines after allogeneic restimulation. ICOS+ cells on the other hand are anergic at the level of proliferation and Th1 and Th2 cytokine production. However, these cells can produce IL-10, and they suppress the allogeneic responses of either primed or naive T cells through inhibition of IL-2 mRNA transcription. Suppression is not mediated by IL-10, but depends on cell-cell contact. Thus a subtype of regulatory T cells in human blood can be activated in the absence of costimulatory signals from CD40, CD80 and CD86, and that they can be identified by expression of ICOS after activation.
Participants receive a dietary intervention designed to promote increased levels of plasma carotenoids, control weight, and to ensure adequacy of micronutrient intake. Participants also undergo a physical activity intervention comprising a moderately low aerobic regimen to raise the usual activity level. Participants also undergo face-to-face counseling, receive educational materials and counseling focused on how to read food labels to estimate grams of fat per serving and serving size, and undergo telephone counseling by a lifestyle intervention counselor twice a week for 4 weeks, then weekly for 2 weeks, twice a month for 5 months, monthly for the subsequent 6 months, and then once every other month for 12 months. Participants complete daily fat gram and step diaries at least three times per week.
In addition to the conservative treatment of the control group, low-level laser therapy (turned off) will be applied for 6 weeks. In the placebo group, laser instrument will be applied in the same way but the device will be turned off during treatment sessions.
Star block copolymers having 3 to 8 arms are formed as a 3D foam scaffold having tailor-made pore sizes that mimic an actual cell size of a specific animal and/or human tissue and/or organs. The pore sizes are made within the elastomeric foams via a salt leaching process wherein a salt of a specific particle size is blended within the star block copolymers and crosslinked as by polyisocyanate compounds. Water or other suitable solvent are utilized to dissolve and leach out the salt leaving an open pore system. Animal and/or human cells are then injected into the 3D elastomeric foam scaffold that contains pendant liquid crystals on the star block copolymer whereby with the aid of nutrients, cells are formed within the pore system that are viable for at least three months. The size of the pore is predetermined to produce a desired cultured cell having a desired size. The tissue and/or cells within the elastomeric scaffold can be applied to animal and/or human tissue and/or organs whereupon they grow and reconstruct the damaged, injured, diseased, etc., area and result in a healthy, repaired, and viable tissue or organ. The elastomeric liquid crystal containing foam scaffold will degrade naturally and/or also be consumed by the growing cells so that it no longer exists. In other words, a specific type of animal or human cell can be culturally produced having a predetermined average cell diameter that is substantially or essentially the same diameter of a natural cell.
Apatinib mesylate has demonstrated good efficacy and acceptable safety in patients with metastatic or recurrent soft tissue sarcoma (STS). A retrospective study has evaluated the efficacy of apatinib in the treatment of advanced soft tissue sarcoma. A total of 31 patients with soft tissue sarcoma were enrolled in this study, including 4 patients receiving apatinib first-line treatment, 8 patients receiving second-line treatment, and 19 patients receiving third-line or post-third-line treatment. The results showed that ORR 33.3%, DCR 75%, and mTTP 4.6 months (1.8-11.6 months). In another multicentric retrospective study of apatinib for osteosarcoma and soft tissue sarcoma, a total of 56 patients were enrolled and 44 were treated with apatinib monotherapy. The overall results showed that ORR was 62.5%, mPFS was 6.6 months, and mOS was 9.9 months. In a phase II multi-center single-arm study results published by Yang Jilong Yang et al at the 2018 AACR conference, ORR and DCR at 3 months also reached 13.95% and 81.39%, respectively. The end point assessment ORR was further increased to 15.25% at the end of the study, because some patients achieved partial remission after a long period of treatment, and the final DCR reached 57.63%. Apatinib had a significant effect in the treatment of stage IV osteosarcoma with failed chemotherapy. Jing Chen et al published a study researching the effectiveness and security in advanced sarcoma patients after apatinib treatment , the results show that 24.3% of subjects to achieve objective response, including 1 case of adenoid vesicular soft tissue sarcoma patients achieved CR, seven adenoid vesicular soft tissue sarcoma patients achieved the objective response, indicates that apatinib is effective and well tolerated in some specific sarcoma subtype.

In this study ,Apatinib mesylate combined with doxorubicin and ifosfamide regimens were evaluated in the treatment of advanced or inoperable STS to determine the potential to achieve better outcomes.
BACKGROUND: Corticosteroids remain contentious as a therapeutic option for IgA nephropathy. We conducted a retrospective cohort study to explore whether corticosteroid therapy is efficient and safe for IgAN patients with moderate proteinuria.
METHODS: A total of 336 patients with renal biopsy-confirmed IgAN, estimated glomerular filtration (eGFR) over 15 mL/min/1.73 m2 and urine protein levels of 0.75-3.5 g/d were enrolled. According to the treatment protocol, we classified the enrolled patients into two groups: one receiving corticosteroids and the other receiving supportive care. Complete remission, partial remission, and no remission were applied to describe the efficacy assessments. The endpoint was defined as a 40% reduction in eGFR, the onset of ESRD, or renal disease-related death.
RESULTS: Clinical and pathological progression risk factors were higher in corticosteroid-treated individuals. Logistic regression analysis revealed that the corticosteroid group was considerably related to a higher remission rate after adjustment for confounding factors. The occurrence of serious adverse events between the two groups was not found to be statistically significantly different. Then, we matched 95 couples of patients with similar baseline levels in both groups by propensity score matching. The results showed that corticosteroid-treated patients showed higher overall and complete remission rates than untreated patients. However, due to the relatively short follow-up period, no significant differences in the incidence of endpoint and survival analyses have been observed thus far.
CONCLUSION: Corticosteroid therapy may benefit IgAN patients with moderate proteinuria via proteinuria reduction and renal function preservation.
BACKGROUND Sinonasal rhabdomyosarcoma (RMS) is a rare malignancy in children and adolescents. It is aggressive and locally invasive, and can require local postoperative radiotherapy. This report presents the case of a 16-year-old girl with a sinonasal-cutaneous fistula following excision and radiotherapy for rhabdomyosarcoma, which required reconstructive surgery using an expanded forehead flap. CASE REPORT We report the case of a16-year-old girl who was referred to our clinic with sinonasal-cutaneous fistula. Prior to presentation at our department, she presented with bilateral intermittent nasal congestion 3 years ago. At a local hospital, orbital computed tomography and nasal endoscopic biopsy revealed an embryonal rhabdomyosarcoma (ERMS). One month later, skull base tumor resection, nasal cavity and sinus tumor resection, and low-temperature plasma ablation were performed at a local hospital. Two weeks after the operation, the patient received intensity-modulated radiation therapy for a total of 50 Gy. Chemotherapy started 15 days after radiotherapy, using a vincristine, dactinomycin, and cyclophosphamide (VAC) regimen. Approximately 1 month later, an ulcer appeared at the nasal root and the lesion gradually expanded. The patient was referred to our hospital due to the defect. Firstly, a tissue expander was implanted at the forehead for 7 months. Then, the skin around the defect was trimmed and forehead flap was separated to repair the lining and external skin. The flap survived well 1-year after the operation. CONCLUSIONS This report highlights the challenges of post-radiation reconstructive surgery and describes how an expanded forehead flap can achieve an acceptable cosmetic outcome in a patient with a sinonasal-cutaneous fistula.
FIELD: polymers, pharmacy. SUBSTANCE: invention describes cross-linked copolymers based on uncross-linked polycarboxylic polymers and cross-linking agent comprising at least two amino-functions. Indicated uncross-linked copolymers comprise at least one polycarboxylic polysaccharide and at least other uncross-linked polycarboxylic polymer that is not poly-carboxylic polysaccharide. Polycarboxylic polymer is taken among group including polycarboxylic polyacids or their partially or totally substituted derivatives, for example, their esters, amides or salts, copolymers comprising links of the above indicated polycarboxylic acids or their named derivatives, or mixture of said polycarboxylic polymers and/or their named derivatives and/or their polymers. Invention relates also to pharmaceutical compositions used for controlled release of active component, in part, in large intestine. EFFECT: improved method of synthesis, valuable properties of polymers. 19 cl, 2 dwg, 7 ex
The study medication (Jardiance) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death. The generic name is empagliflozin and will be provided by Boehringer-Ingelheim. If the patient is randomized into the study drug group patients will receive empagliflozin 10 mg tablets once daily for a duration of 6 months.
Mammography is considered a fundamental part of diagnosis in modern health care services. It provides low dose soft tissue imaging of normal structure and pathology within the breast. A mammogram can be performed on both asymptomatic and symptomatic women with palpable lumps and any other complaints. It is an appropriate source of early detection for breast cancer in diagnostic imaging. This screening practice is associated with a strong reduction in mortality in breast cancer as many guidelines have already published. Thus, Mammography has been demonstrated as a "Gold Standard" technique used for Breast cancer Imaging.

Besides, a strong reliance on Mammographic examination that most of the females may experience breast pain and discomfort while achieving standard compression in mammography which is necessary for optimal image quality a number of trials have been published. Moreover, previously reported that anxiety-related psychological pain, false perception or fear of discomfort is a factual reason for pain and discomfort while performing mammography. Breast pain is also associated with the menstrual cycle and noncyclic (trauma, surgery, and infection). Although, pain, discomfort, anxiety and false beliefs is a major reason to discontinue this procedure and over the past decades taking part in mammography is quite challenging for many women.

Premeditated mammography with the aid of analgesics is one of the most suitable interventions for diminishing pain. In this current study, paracetamol is used as an intervention for diminishing pain during mammography. Previously, a study declared that paracetamol can reduce mild pain and most people can take this medicine safely. We planned this study to evaluate the effective strategy to cope with the pain and discomfort among women undergoing mammography.
The invention belongs to the technical field of biological medicines, and particularly relates to a medicine for treating stomach diseases and a preparation method thereof. The pharmaceutical composition for treating the stomach illness comprises a medicament A and a medicament B, wherein the medicament A comprises rhizoma polygonati, ageratum, dried orange peel, liquorice, rutin, hawthorn, endothelium corneum gigeriae galli, snow lotus herb and cordyceps sinensis powder, and the medicament B comprises flavonol, amino acid, aromatic aldehydes, vitamins and mineral substances. Has obvious curative effect on hypertension, hyperlipemia, cerebral vessels and cardiovascular vessels. Has special curative effect on gastritis, gastric ulcer and duodenitis. For many years, the clinical evaluation of treating gastropathy is three-effect good medicine: (1) quick acting, good and quick effect. (2) High efficiency, incredible effect and unexpected good effect. (3) Long effect and no recurrence. It can supplement deficiency and damage to human body, strengthen healthy qi, and is an ideal good product for curing diseases and pains. Whether male or female, the patient has disease or not. After taking for several months, the essence, qi and spirit can be well changed.
Aim: Evaluate the influence of exercise, in different times, on quality of life, sleep and clinical parameters in people living with HIV/AIDS (PLHA). Methods: Intervention study, prospective, a cohort with 17 PLHA participants of the exercise program, higher than 18 years, under antiretroviral therapy with CD4+ ≥ 350/mm3. Research Ethical Committee of the institution approved the study and the participants sign the informed consent and informed. All subjects underwent an exercise program in conformity to American College of Sports Medicine, 3 times per week during 40 minutes. Were evaluated the quality of life (QoL) with the Quality of Life - HAT - QoL and the sleep quality (SQ) with the Pittsburg questionnaire. The subjects were evaluated before the start of exercise program and in three times: short-term (2 to 4 months), medium-term (between 5 and 17 months) and long-term (between 18 to 25 months).
The invention belongs to the technical field of skin care products, and particularly relates to a skin repair composition and application thereof. The skin repair composition comprises the following components: liquid paraffin, oxidized corn oil, linolenic acid, linoleic acid, palmitic acid, vitamin E, stearic acid and borneol. The linolenic acid and linoleic acid in the composition can promote skin regeneration and reconstruction, and better improve skin moisture retention; by intervening the binding of the stratum corneum, transdermal water loss is prevented and lipid barriers are enhanced. The composition can be used in skin repair ointment for treating bedsore mild symptoms. The ointment comprises the following components in percentage by mass: 40-70% of skin repair composition and 10-20% of sodium hyaluronate; collagen 5-10%; 5-10% of shikonin; 10-20% of salicylic acid. The shikonin and the salicylic acid in the ointment have anti-inflammatory and bactericidal effects, and are beneficial to repairing bedsore affected parts.
The project population will be 40 pregnant women with opioid use disorder inducted as outpatients to buprenorphine-naloxone maintenance. Subject treatment data, including medical and obstetric histories, drug use histories, demographic information and psychosocial information will be extracted from patient charts. Weekly urine toxicology testing will provide information regarding other substance use/misuse during the time of study participation. Study participants will undergo 2 60 minute maternal and fetal neurophysiologic monitoring sessions on one day at 4 points during gestation: 24, 28, 32 and 36 weeks, at times of trough (just before sublingual buprenorphine-naloxone or methadone daily dose) and peak (2 1/2 hours after dosing) maternal drug levels. Fetal cardiac (heart rate, heart rate variability, heart rate accelerations) and movement (total fetal movement, number and duration of movement bouts) and the correlation between the two (fetal heart rate-movement coupling) will be determined. Maternal physiologic measures will include heart period and variability, vagal tone, skin conductance and respiratory data. All maternal and fetal measures, with the exception of blood pressure, will be computed in 1-minute intervals and averaged over the 60 min recording. Infant birth data and birth parameters, and neonatal abstinence syndrome scores will be extracted from patient charts. Infants will undergo neurobehavioral testing using the Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale, a 30 minute harmless assessment of infant functioning, on days 3, 14 and 30 of life.
This trial was conducted in 2 phases. During the acute-phase, i.v. ketamine was administered thrice-weekly for up to 2 weeks.Those who achieved depressive symptom remission received continuation-phase treatment that consisted of once-weekly i.v. ketamine infusions for 4 additional weeks. Remission could occur after any of the 6 acute-phase infusions, at which point the next infusion was the first (of four) continuation-phase infusions. Individuals who remitted during acute-phase and completed continuation-phase treatment had 4 additional weekly post-continuation follow-up visits.
Depression, and suicidal ideation and behavior can occur in patients treated with XYWAV.

In Study 1 [see Clinical Studies (14.1)], depression and depressed mood were reported in 3% and 4%, respectively, of patients treated with XYWAV. Two patients (1%) discontinued XYWAV because of depression, but in most cases, no change in XYWAV treatment was required.

In Study 2 [see Clinical Studies (14.3)], depression and depressed mood were reported in 1 patient (1%) and in 5 patients (3%), respectively, of patients treated with XYWAV, all of whom continued XYWAV treatment.

In clinical trials of Xyrem (same active moiety as XYWAV) in adult patients with narcolepsy (n=781), there were two suicides and two attempted suicides in patients treated with Xyrem, including three patients with a previous history of depressive psychiatric disorder. Of the two suicides, one patient used Xyrem in conjunction with other drugs. Xyrem was not involved in the second suicide. Adverse reactions of depression were reported by 7% of 781 patients treated with Xyrem, with four patients (<1%) discontinuing because of depression. In most cases, no change in Xyrem treatment was required. In a clinical trial with Xyrem in pediatric patients with narcolepsy (n=104), one patient experienced suicidal ideation and two patients reported depression while taking Xyrem.

The emergence of depression in patients treated with XYWAV requires careful and immediate evaluation. Patients with a previous history of a depressive illness and/or suicide attempt should be monitored carefully for the emergence of depressive symptoms while taking XYWAV.
This group will do a 12-week high intensity exercise program. The subjects will exercise by increasing how much they lift their knees while walking on treadmill. The exercise will also involve controlling the impact of the feet on the treadmill. A TV placed in front of the treadmill shows how high individuals need to lift their knees. How much participants need to lift their knees is calculated based on real-time heart rate readings.
After 6 cycles of first-line treatment (Androgen deprivation therapy + abiraterone acetate along with prednisone) , patients will receive robot assisted laparoscopic prostatectomy + enlarged pelvic lymph node dissection (ePLND) within 9 months of being diagnosed. The ADT+abiraterone treatment will be maintained after surgery.
A communication system for a motor vehicle having a plurality of seats includes a plurality of occupant sensors each detecting the presence of a passenger in a respective one of the seats. Passenger identification means identifies each of the passengers detected by the occupant sensors. A database stores medical information in association with each of the identified passengers. Detecting means detects that the motor vehicle has been in a crash. A transmitter wirelessly communicates with a remote emergency responder. An electronic processor responds to the detecting means detecting that the motor vehicle has been in a crash by causing the transmitter to transmit a signal to the remote emergency responder. The signal informs the remote emergency responder of the respective medical information and seat location associated with each passenger of the motor vehicle.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention refers to veterinary science, namely to therapy of internal nontransmitting diseases, particularly to drugs for chicken hepatosis prevention. The agent for chicken hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; phenol 0.004-0.005 mg; physiological solution up to 1 ml. The agent is introduced to chickens and chicks in dose 0.2 ml/kg of body weight subcutaneously or intramuscularly. ^ EFFECT: invention allows higher effectiveness of chicken hepatosis prevention. ^ 4 tbl
Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.